ReviewInternational journal of chronic obstructive pulmonary disease2016
Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁.
Review in International journal of chronic obstructive pulmonary disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review.Respiratory research · 2022Pooled it
- Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-ActingComputational and mathematical methods in medicine · 2022Pooled it
- Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal.BMJ (Clinical research ed.) · 2019Pooled it
- Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2019Pooled it
- Normal spirometry with high and asthma-defining bronchodilator responsiveness: An appraisal from real-life data.Lung India : official organ of Indian Chest Society · 2026Article
- Impaired lung deformation during expiration in chronic obstructive pulmonary disease using four-dimensional dynamic-ventilation CT.Quantitative imaging in medicine and surgery · 2026Article
- Article
- Comment on "Predicting VOSports medicine (Auckland, N.Z.) · 2026Article
- Correlation between questionnaire on air pollution-related factors and chronic respiratory diseases: a case study of Minhang District, Shanghai.BMC public health · 2025Article
- Beyond Smoking: Emerging Drivers of COPD and Their Clinical Implications in Low- and Middle-Income Countries: A Narrative Review.Journal of clinical medicine · 2025Review
- Trends in Exposure to Respirable Dust and Respirable Crystalline Silica Among Lithium Mine Workers in Western Australia.Safety and health at work · 2024Article
- Care pathways versus usual care for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2024Article
- Plasmonic Alloys Enhanced Metabolic Fingerprints for the Diagnosis of COPD and Exacerbations.ACS central science · 2024Article
- Development and Application of a Virtual Imaging Trial Framework for Longitudinal Quantification of Emphysema in CT.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Spirometric Interpretation and Clinical Relevance According to Different Reference Equations.Journal of Korean medical science · 2024Article
- Single-Breath Simultaneous Measurement of DLInternational journal of chronic obstructive pulmonary disease · 2024Observational
- Serum levels of HMW adiponectin and its receptors are associated with cytokine levels and clinical characteristics in chronic obstructive pulmonary disease.Open medicine (Warsaw, Poland) · 2024Article
- Article
- Impulse Oscillometry as a Diagnostic Test for Pulmonary Emphysema in a Clinical Setting.Journal of clinical medicine · 2023Article
- Comparison of newly diagnosed COPD patients and the non-COPD residents in Shanghai Minhang District.Frontiers in public health · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
COPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and "frequent exacerbators". Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as "asthma COPD overlap syndrome". Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.